News & Updates

Early chemo switch not beneficial in patients with high circulating tumor cells

06 Aug 2024 by

In patients with metastatic breast cancer who failed to clear circulating tumor cells (CTCs) after one cycle of first-line chemotherapy, switching to a different chemotherapy does not improve survival or delay progression, the phase III SWOG S0500 trial has shown.

Early chemo switch not beneficial in patients with high circulating tumor cells

06 Aug 2024

Surgery or radiation for breast cancer may be unnecessary after successful chemotherapy

02 Aug 2024 by

Surgery or radiation may not be the best option for continued treatment once women with breast cancer have successfully responded to chemotherapy, new research shows.

Surgery or radiation for breast cancer may be unnecessary after successful chemotherapy

02 Aug 2024

$Oncolytic immunotherapy promising in sorafenib-refractory HCC$

Oncolytic immunotherapy promising in sorafenib-refractory HCC

02 Aug 2024 by

Asian patients with advanced hepatocellular carcinoma (HCC) refractory to sorafenib may benefit from an investigational oncolytic immunotherapy known as JX-594, as it showed antitumor activity in a recent phase II trial.

Oncolytic immunotherapy promising in sorafenib-refractory HCC

02 Aug 2024

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma

22 Jul 2024 by

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA_1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma

22 Jul 2024

NGS could guide ovarian cancer treatment

11 Jul 2024 by

The use of next generation sequencing (NGS) could help identify patients with ovarian cancer who would benefit from targeted therapies, according to a small retrospective study from Korea.

NGS could guide ovarian cancer treatment

11 Jul 2024

Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC

02 Jul 2024 by

Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.

Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC

02 Jul 2024

Subcutaneous atezolizumab favoured over intravenous infusion

02 Jul 2024 by

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

Subcutaneous atezolizumab favoured over intravenous infusion

02 Jul 2024

Legume intake reduces colorectal cancer risk

30 Jun 2024 by

Eating legumes may help avert the development of colorectal cancer, according to a study that has found an inverse association between legume consumption and colorectal cancer risk.

Legume intake reduces colorectal cancer risk

30 Jun 2024

Pembrolizumab effective against mucosal melanoma and bladder cancer

12 Jun 2024 by

Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer.

Pembrolizumab effective against mucosal melanoma and bladder cancer

12 Jun 2024

Melanoma mortality rates to drop by 2050

12 Jun 2024 by

Mortality rates of melanoma are predicted to fall by 2050, but the number of individuals dying from the disease will increase due to population growth and ageing.

Melanoma mortality rates to drop by 2050

12 Jun 2024

News & Updates

Filter by Specialty:

Specialty:

Early chemo switch not beneficial in patients with high circulating tumor cells

Early chemo switch not beneficial in patients with high circulating tumor cells

Surgery or radiation for breast cancer may be unnecessary after successful chemotherapy

Surgery or radiation for breast cancer may be unnecessary after successful chemotherapy

Oncolytic immunotherapy promising in sorafenib-refractory HCC

Oncolytic immunotherapy promising in sorafenib-refractory HCC

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma

[HKU Medical Grand Rounds] Angels and demons: Immunotherapy for treatment of advanced hepatocellular carcinoma

NGS could guide ovarian cancer treatment

NGS could guide ovarian cancer treatment

Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC

Neoadjuvant cycles do not alter perioperative nivolumab benefit in resectable NSCLC

Subcutaneous atezolizumab favoured over intravenous infusion

Subcutaneous atezolizumab favoured over intravenous infusion

Legume intake reduces colorectal cancer risk

Legume intake reduces colorectal cancer risk

Pembrolizumab effective against mucosal melanoma and bladder cancer

Pembrolizumab effective against mucosal melanoma and bladder cancer

Melanoma mortality rates to drop by 2050

Melanoma mortality rates to drop by 2050